About ipsen sa - IPSEF
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. It operates through the following segments: Specialty Care. The Specialty Care segment focuses on oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and rare diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.
IPSEF At a Glance
Ipsen SA
65, quai Georges Gorse
Boulogne-Billancourt, Ile-de-France 92650
| Phone | 33-1-58-33-50-00 | Revenue | 3.38B | |
| Industry | Pharmaceuticals: Major | Net Income | 696.67M | |
| Sector | Health Technology | 2023 Sales Growth | 6.354% | |
| Fiscal Year-end | 12 / 2024 | Employees | 5,325 | |
| View SEC Filings |
IPSEF Valuation
| P/E Current | 12.734 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 14.153 |
| Price to Sales Ratio | 2.939 |
| Price to Book Ratio | 2.331 |
| Price to Cash Flow Ratio | 10.90 |
| Enterprise Value to EBITDA | 9.65 |
| Enterprise Value to Sales | 2.917 |
| Total Debt to Enterprise Value | 0.052 |
IPSEF Efficiency
| Revenue/Employee | 634,965.08 |
| Income Per Employee | 130,830.215 |
| Receivables Turnover | 3.534 |
| Total Asset Turnover | 0.521 |
IPSEF Liquidity
| Current Ratio | 1.167 |
| Quick Ratio | 0.989 |
| Cash Ratio | 0.325 |
IPSEF Profitability
| Gross Margin | 75.102 |
| Operating Margin | 20.748 |
| Pretax Margin | 24.349 |
| Net Margin | 20.604 |
| Return on Assets | 10.288 |
| Return on Equity | 17.135 |
| Return on Total Capital | 14.085 |
| Return on Invested Capital | 15.033 |
IPSEF Capital Structure
| Total Debt to Total Equity | 12.102 |
| Total Debt to Total Capital | 10.795 |
| Total Debt to Total Assets | 7.321 |
| Long-Term Debt to Equity | 8.925 |
| Long-Term Debt to Total Capital | 7.962 |